BMS - PRWeb Press Release Group http://www.rsspad.com/rss2/44064.xml BMS - Powered by PRWeb and RSSPad en xml@emediawire.com xml@emediawire.com 30 Bristol-Myers Squibb Company Today Announced New Data from the E.A.R.L.Y. Study (ETV-079) http://www.prweb.com/releases/2008/04/prweb894794.htm Bristol-Myers Squibb Company today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naïve adult chronic hepatitis B patients with BARACLUDE® (entecavir) resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week results (primary endpoint). (PRWeb Apr 26, 2008)

Read the full story at http://www.prweb.com/releases/2008/04/prweb894794.htm

]]> Sat, 26 Apr 2008 07:00:00 GMThttp://www.prweb.com/releases/2008/04/prweb894794.htm BARACLUDE (Entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment In Nucleoside-Naive Chronic Hepatitis B Patients http://www.prweb.com/releases/2008/03/prweb796984.htm Data Indicate Pre-existing Lamivudine Resistance Predisposes Patients to Higher Rates of BARACLUDE Resistance (PRWeb Mar 24, 2008)

Read the full story at http://www.prweb.com/releases/2008/03/prweb796984.htm

]]> Mon, 24 Mar 2008 07:00:00 GMThttp://www.prweb.com/releases/2008/03/prweb796984.htm